Evidence map›Paper›PMID 40860786›Full record

ArticleOxford medical case reports2025

G-CSF-induced Aortitis in an elderly woman successfully managed with prednisolone: a case report and literature review.

Taeko Kurosawa, Masahiro Ohara, Ayako Nakame, Yuki Ichinose, Akihiro Fujimoto, Asami Nukui, Kei Yamaguchi, Aya Asano, Hiroko Shimada, Hideki Yokogawa and 5 more

Abstract readCase Reports
In one paragraph

Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Taeko KurosawaDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.ORCID https://orcid.org/0000-0003-4174-5052
Masahiro OharaDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Ayako NakameDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Yuki IchinoseDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.ORCID https://orcid.org/0000-0001-8308-901X
Akihiro FujimotoDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.ORCID https://orcid.org/0000-0003-4261-7984
Asami NukuiDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Kei YamaguchiDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Aya AsanoDepartment of Breast Oncology, Saitama Medical University Hospital, 38 Morohongo, Moroyama-machi,Iruma-gun, Saitama 350-0495, Japan.
Hiroko ShimadaDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Hideki YokogawaDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Kazuo MatsuuraDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Hiroshi IshiguroDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Takahiro HasebeDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Akihiko OsakiDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Toshiaki SaekiDepartment of Breast Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer incidence among old is increasing. Since age is important risk factor for febrile neutropenia (FN), use of granulocyte-colony stimulating factor (G-CSF) and its complication is clinically important. A 72-year old woman has completed definitive surgery for left breast cancer and was started on postoperative chemotherapy. After 12 doses of paclitaxel, she received 1st cycle of epirubicin and cyclophosphamide (day 1), and pegfilgrastim, a pegylated G-CSF to decrease the risk of FN (day 2). On day 13, she was admitted due to persistent fever since day 9. Laboratory tests revealed elevated neutrophil counts and C-reactive protein. Despite empirical antibiotics, her fever persisted and severe back pain developed (day 15). Contrast-enhanced computed tomography revealed wall thickening and increased density around the aortic arch and brachiocephalic artery. Diagnosis of pegfilgrastim-induced vasculitis was made after excluding autoimmune vasculitis. Prednisolone (60 mg/day) was administered and the fever and back pain subsided the following day.

Indexed as

Aortitisbreast cancerFilgrastimgranulocyte-colony stimulating factorPegfilgrastim

Identifiers

PMID40860786
PMCPMC12375805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.